The spring newsletter from the Stanford ME/CFS Initiative lead by Dr. Montoya is out and it's time, once again, to take stock of this important program. With Stanford containing some of the brightest minds and best tools in medicine, studies coming out of the University have their own kind of legitimacy.
[fright]
[/fright] Montoya first stumbled onto chronic fatigue syndrome in 2004 but by 2005 he knew he wanted to study it. When he told his mentor that he was told he'd wind up like a drunk in the gutter if he did so.
Mammoth Single Donation
Montoya courageously persisted, however, and over time became one of our most compelling spokespeople. In 2008 he received a $5 million dollar grant from an anonymous donor. When asked if the money would make a difference, Montoya said give me five years. In 2009 the Stanford ME/CFS Initiative was borne.
Getting the Initiative off the ground couldn't have come easy. Dr. Montoya appeared to be successful, though, in enrolling members of the Stanford faculty to study a disease that most of them probably had little interest in. Ultimately he was able to put together an array of studies examining the genes, the immune system, the brain, the heart and pathogens, plus he he participated in the Lipkin/Hornig blood cytokine studies and the Synergy trial. In 2014 Montoya got the Stanford School of Medicine to sponsor what turned out to be a very successful Symposium on ME/CFS.
Impactful Symposium
The March 2014 Stanford Symposium on ME/CFS packed more bang for the buck than any conference I could remember. Jarred Younger's findings suggested leptin could be the make or break immune factor for ME/CFS. Kaushal's gene expression findings suggested ME/CFS was very similar to ‘systemic inflammatory syndrome’. The Zinn's found that ME/CFS patients were in a hypometabolic state, highlighted the brainstem and suggested ME/CFS might be a "limbic encephalitis". Montoya called his cytokine results (high pro-inflammatory/low anti-inflammatory") the "perfect storm", and Dr. Byron Hyde called Dr. Zeineh's presentation the MRI results the "most amazing" of its kind that he'd seen in ME/CFS.
Five years after its launch the Stanford ME/CFS Initiative finally appeared to be humming and the stage appeared to be set for a series of important findings. Particularly interesting was Montoya's 600 person (200 ME/CFS, 400 controls) study involving Dr. Mark Davis's mighty CyToF immune machine.
2015 Newsletter
[fright]
[/fright]That, however, has been it. A year ago Health Rising published a blog titled "Tipping Point: The Stanford Chronic Fatigue Initiative's Big Year is here" which highlighted the few publications to have come out of the group. (Younger published his leptin paper in 2013 and Zeineh published his small brain study in 2015). The 2015 Stanford ME/CFS Initiative Newsletter suggested that publication for most studies was just around the corner. It stated that:
2016 Newsletter
The Spring 2016 Newsletter, however, looked in many ways like the 2015 newsletter.
The first thing to note is that Montoya and the Stanford ME/CFS Initiative are engaged in a substantial and ambitious body of work which if successful could tell us much. Montoya has also continued to reach out to begin or at least fashion new, intriguing studies. The Universal Pathogen study, in particular, would fill a major hole in pathogen research.
Eight years after getting the big donation (and more donations surely followed), and three years after Montoya's deadline ("give me five years") the Stanford ME/CFS Initiative still, however, has published just two studies. Since the promising Stanford Symposium of two years ago, it has published just one.
[fright]
[/fright]A pattern has emerged of over-promise and delayed results - something that honestly may not be too uncommon in medical research. Much of the 2016 newsletter looked like the 2015 one. The return on investment (ROI) from that initial investment could change quickly but seems pretty low thus far.
In the meantime the University of Alabama at Birmingham lured away Jared Younger with a promise of his own lab, and the Zinn's moved to Chicago to work with Lenny Jason where they promptly published a study using new ME/CFS patients. Dr. Montoya also lost the researcher (Kaushal) behind the gene expression project.
On the other hand, Dr. Montoya has continued to recruit researchers including a PhD and a gastroenterologist (Universal Pathogen Study) and an endocrinologist, and has, thanks to a donation, acquired the services of a much needed biostatistician, Donn Garvert MS. He also has a new researcher working on the gene expression study, and recruited a new research assistant. He's also working with immune expert Mark Davis and Holden Maecker, the Director of the Human Immune Monitoring project.
Full Plate?
Dr. Montoya is still the Director of the National Reference Laboratory for the Study and Diagnosis of Toxoplasmosis; is a doctor seeing patients at the Infectious Disease Clinic and after 2009, has been the Director of the Stanford ME/CFS Initiative; i.e. he has a very full plate. (Montoya has co-authored over 20 studies/papers on toxoplasmosis since the Stanford ME/CFS Initiative began in 2009. His 2013 ME/CFS valganciclovir study, however, took five years after data collection had ended (2008) to get published.)
Is This the Year?
The Initiative still holds great promise, and research studies can take years. The 600 person immune study was reportedly the largest Mark Davis had ever run, and could tell us much about ME/CFS. If the 2016 newsletter is correct several major studies may be close to publication. Eight years after Montoya received his big donation 2016 will, hopefully, be the year of the Stanford Chronic ME/CFS Initiative.
[fright]
Mammoth Single Donation
Montoya courageously persisted, however, and over time became one of our most compelling spokespeople. In 2008 he received a $5 million dollar grant from an anonymous donor. When asked if the money would make a difference, Montoya said give me five years. In 2009 the Stanford ME/CFS Initiative was borne.
Getting the Initiative off the ground couldn't have come easy. Dr. Montoya appeared to be successful, though, in enrolling members of the Stanford faculty to study a disease that most of them probably had little interest in. Ultimately he was able to put together an array of studies examining the genes, the immune system, the brain, the heart and pathogens, plus he he participated in the Lipkin/Hornig blood cytokine studies and the Synergy trial. In 2014 Montoya got the Stanford School of Medicine to sponsor what turned out to be a very successful Symposium on ME/CFS.
Impactful Symposium
The March 2014 Stanford Symposium on ME/CFS packed more bang for the buck than any conference I could remember. Jarred Younger's findings suggested leptin could be the make or break immune factor for ME/CFS. Kaushal's gene expression findings suggested ME/CFS was very similar to ‘systemic inflammatory syndrome’. The Zinn's found that ME/CFS patients were in a hypometabolic state, highlighted the brainstem and suggested ME/CFS might be a "limbic encephalitis". Montoya called his cytokine results (high pro-inflammatory/low anti-inflammatory") the "perfect storm", and Dr. Byron Hyde called Dr. Zeineh's presentation the MRI results the "most amazing" of its kind that he'd seen in ME/CFS.
Five years after its launch the Stanford ME/CFS Initiative finally appeared to be humming and the stage appeared to be set for a series of important findings. Particularly interesting was Montoya's 600 person (200 ME/CFS, 400 controls) study involving Dr. Mark Davis's mighty CyToF immune machine.
2015 Newsletter
[fright]
- Pathogen Study - A manuscript featuring "exciting" results from a collaboration with Ian Lipkin and Mady Hornig was under preparation for submission to a journal.
- Gene and Immune Study - The final analysis of the big gene expression and immune study with Mark Davis was finishing up with a manuscript submission expected shortly.
- Cardiovascular Health - Two manuscripts examining cardiovascular health and exercise in ME/CFS were in preparation for publication.
- Zinn's Brain Imagining - Two manuscripts from the Zinn's were in review for publication.
- Genetic and Immune Study - The final analysis of a genetic and immune study from a Department of Defense (DoD) grant was underway and a manuscript was due to begin shortly.
- A gene expression Lyme Disease study with Mark Davis - to begin in late spring of 2015
- A Severely Ill Patients study - to begin in the summer of 2015
- An HPA axis Biomarkers study - to begin in the summer of 2015
- A Universal Pathogen study looking for pathogens in the guts, lymph nodes, bone marrow and NK cells - no date for beginning mentioned.
2016 Newsletter
The Spring 2016 Newsletter, however, looked in many ways like the 2015 newsletter.
- Zeineh Brain Imaging Study - Progress was made in the Zeineh grant application. It was submitted but turned down and is being resubmitted.
- Montoya/Lipkin/Hornig Pathogen Study -As in 2015, it stated that the group is still in the process of preparing a manuscript.
- Gene Expression and Immune Data w/ Mark Davis - Jill Anderson, reported (similar to 2015) that the data analysis from the big 600 person study was finishing up, and a manuscript would be submitted shortly.
- Cardiovascular and Endothelial Cell Study - Jill Anderson reported that Dr. Hadad had a new finding he was hoping to incorporate in a study. She reported (as in 2015), that two manuscripts for cardiovascular studies including one examining endothelial function and cytokine levels after exercise are being prepared for publication.
- The Zinn's Brain Studies - as in 2015, two studies by the Zinn's were reported to be in preparation for publication. (The Zinn's gathered and presented their data at the Symposium but are now listed as collaborators of Dr. Maldonado.) The Zinn's moved to Chicago some time ago where they redid one of their studies with new participants and published it. They also published a review paper and expect several more studies to be published soon.
- DoD Gene and Immune Profiling Study - As was reported last year the gene and immune profiling results are still being prepared for publication. A biostatistician has been added to the project
- The Lyme Disease Study with Mark Davis - has moved forward and begun accepting patients for recruitment.
- The severely ill patients study - reported last year to begin in the summer of 2015, the severely ill patients study is now slated to begin "within the next year".
- The Universal Pathogen Study - no date was given for startup last year. Jill Anderson reported that a grant submission is expected in fall (with the study, if the submission is successful, presumably to begin in 2017.)
- The HPA axis study - expected in begin in summer of 2015 - the HPA axis study is now expected to begin in late Spring of 2016
- New GWS Study - Montoya and Zeineh have submitted a grant application for an entirely new project on brain and immune signatures in GWS.
- ME/CFS Brain and Tissue Bank - the newsletter reported that the Initiative has begun to address the regulatory hurdles of establishing a brain and tissue bank.
The first thing to note is that Montoya and the Stanford ME/CFS Initiative are engaged in a substantial and ambitious body of work which if successful could tell us much. Montoya has also continued to reach out to begin or at least fashion new, intriguing studies. The Universal Pathogen study, in particular, would fill a major hole in pathogen research.
Eight years after getting the big donation (and more donations surely followed), and three years after Montoya's deadline ("give me five years") the Stanford ME/CFS Initiative still, however, has published just two studies. Since the promising Stanford Symposium of two years ago, it has published just one.
[fright]
In the meantime the University of Alabama at Birmingham lured away Jared Younger with a promise of his own lab, and the Zinn's moved to Chicago to work with Lenny Jason where they promptly published a study using new ME/CFS patients. Dr. Montoya also lost the researcher (Kaushal) behind the gene expression project.
On the other hand, Dr. Montoya has continued to recruit researchers including a PhD and a gastroenterologist (Universal Pathogen Study) and an endocrinologist, and has, thanks to a donation, acquired the services of a much needed biostatistician, Donn Garvert MS. He also has a new researcher working on the gene expression study, and recruited a new research assistant. He's also working with immune expert Mark Davis and Holden Maecker, the Director of the Human Immune Monitoring project.
Full Plate?
Dr. Montoya is still the Director of the National Reference Laboratory for the Study and Diagnosis of Toxoplasmosis; is a doctor seeing patients at the Infectious Disease Clinic and after 2009, has been the Director of the Stanford ME/CFS Initiative; i.e. he has a very full plate. (Montoya has co-authored over 20 studies/papers on toxoplasmosis since the Stanford ME/CFS Initiative began in 2009. His 2013 ME/CFS valganciclovir study, however, took five years after data collection had ended (2008) to get published.)
Is This the Year?
The Initiative still holds great promise, and research studies can take years. The 600 person immune study was reportedly the largest Mark Davis had ever run, and could tell us much about ME/CFS. If the 2016 newsletter is correct several major studies may be close to publication. Eight years after Montoya received his big donation 2016 will, hopefully, be the year of the Stanford Chronic ME/CFS Initiative.
Attachments
Last edited: